Literature DB >> 25549151

Spatial resolution and image qualities of Zr-89 on Siemens Biograph TruePoint PET/CT.

Young Sub Lee1, Jin Su Kim, Jung Young Kim, Byung Il Kim, Sang Moo Lim, Hee-Joung Kim.   

Abstract

PURPOSE: Zirconium-89 (t(1/2)=78.41 hours) is an ideal metallic radioisotope for immuno-positron emission tomography (PET), given that its physical half-life closely matches the biological half-life of monoclonal antibodies. In this study, the authors measured the spatial resolution and image quality of Zr-89 PET and compared the results against those obtained using F-18 PET, which is widely regarded as the gold standard for comparison of imaging characteristics.
MATERIALS AND METHODS: The spatial resolution and image qualities of Zr-89 were measured on the Siemens Biograph Truepoint TrueV PET/CT scanner, partly according to NEMA NU2-2007 standards. For spatial resolution measurement, the Zr-89 point source was located at the center of the axial field of view (FOV) and offset 1/4 axial FOV from the center. For image quality measurements, an NEMA IEC Phantom was used. The NEMA IEC Phantom consists of six hot spheres that were filled with Zr-89 solution. Spatial resolution and image quality (%contrast, %background variability [BV], and source to background ratio [SBR]) were assessed to compare the imaging characteristics of F-18 with those of Siemens Biograph Truepoint TrueV.
RESULTS: The transverse and axial spatial resolutions at 1 cm were 4.5 and 4.7 mm for Zr-89, respectively. The %contrast of Zr-89 was 25.5% for the smallest 10 mm sized sphere and 89.8% for the largest 37 mm sized sphere, and for F-18, it was 32.5% for the smallest 10 mm sized sphere and 103.9% for the largest 37 mm sized sphere using the ordered subset expectation maximization (OSEM) reconstruction method. The %BV of F-18 PET was 6.4% for the smallest 10 mm sized sphere and 3.5% for the largest 37 mm sized sphere using the OSEM reconstruction. The SBR of Zr-89 was 1.8 for the smallest 10 mm sized sphere and 3.7 for the largest 37 mm sized sphere, and for F-18, it was 2.0 for the smallest 10 mm sized sphere and 4.1 for the largest 37 mm sized sphere using the OSEM reconstruction method.
CONCLUSIONS: This study assessed Zr-89 imaging characteristics using a Siemens Biograph Truepoint TrueV PET/CT scanner and compared the results with those obtained for F-18 PET. Although spatial resolution and image quality of Zr-89 PET were lower compared with F-18 PET, due to longer positron range and low positron branching ratio, Zr-89 is advantageous for immuno-PET due to well-matched half-life with monoclonal antibodies.

Entities:  

Keywords:  PET; Zr-89; image quality; radioimmunotherapy (RIT); spatial resolution

Mesh:

Substances:

Year:  2014        PMID: 25549151      PMCID: PMC4322956          DOI: 10.1089/cbr.2014.1709

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  14 in total

1.  Dosimetric impact of correcting count losses due to deadtime in clinical radioimmunotherapy trials involving iodine-131 scintigraphy.

Authors:  Ludovic Ferrer; Grégory Delpon; Albert Lisbona; Manuel Bardiès
Journal:  Cancer Biother Radiopharm       Date:  2003-02       Impact factor: 3.099

Review 2.  Immuno-positron emission tomography: shedding light on clinical antibody therapy.

Authors:  Guus A M S van Dongen; Maria J W D Vosjan
Journal:  Cancer Biother Radiopharm       Date:  2010-08       Impact factor: 3.099

3.  Image-quality assessment for several positron emitters using the NEMA NU 4-2008 standards in the Siemens Inveon small-animal PET scanner.

Authors:  Jonathan A Disselhorst; Maarten Brom; Peter Laverman; Cornelius H Slump; Otto C Boerman; Wim J G Oyen; Martin Gotthardt; Eric P Visser
Journal:  J Nucl Med       Date:  2010-03-17       Impact factor: 10.057

4.  Evaluation of accuracy in activity calculations for the conjugate view method from Monte Carlo simulated scintillation camera images using experimental data in an anthropomorphic phantom.

Authors:  Lena Jönsson; Michael Ljungberg; Sven-Erik Strand
Journal:  J Nucl Med       Date:  2005-10       Impact factor: 10.057

Review 5.  PET versus SPECT: strengths, limitations and challenges.

Authors:  Arman Rahmim; Habib Zaidi
Journal:  Nucl Med Commun       Date:  2008-03       Impact factor: 1.690

6.  Performance measurement of the microPET focus 120 scanner.

Authors:  Jin Su Kim; Jae Sung Lee; Ki Chun Im; Su Jin Kim; Seog-Young Kim; Dong Soo Lee; Dae Hyuk Moon
Journal:  J Nucl Med       Date:  2007-08-17       Impact factor: 10.057

7.  Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose.

Authors:  Joseph G Rajendran; Ajay K Gopal; Darrel R Fisher; Larry D Durack; Ted A Gooley; Oliver W Press
Journal:  J Nucl Med       Date:  2008-04-15       Impact factor: 10.057

Review 8.  Radioimmunotherapy for Non-Hodgkin's Lymphoma.

Authors:  Arati V Rao; Gamal Akabani; David A Rizzieri
Journal:  Clin Med Res       Date:  2005-08

9.  Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study.

Authors:  Yuni K Dewaraja; Scott J Wilderman; Kenneth F Koral; Mark S Kaminski; Anca M Avram
Journal:  Cancer Biother Radiopharm       Date:  2009-08       Impact factor: 3.099

10.  Standardized methods for the production of high specific-activity zirconium-89.

Authors:  Jason P Holland; Yiauchung Sheh; Jason S Lewis
Journal:  Nucl Med Biol       Date:  2009-07-29       Impact factor: 2.408

View more
  6 in total

1.  Quantitative Whole-Body Imaging of I-124-Labeled Adeno-Associated Viral Vector Biodistribution in Nonhuman Primates.

Authors:  Douglas J Ballon; Jonathan B Rosenberg; Edward K Fung; Anastasia Nikolopoulou; Paresh Kothari; Bishnu P De; Bin He; Alvin Chen; Linda A Heier; Dolan Sondhi; Stephen M Kaminsky; Paul David Mozley; John W Babich; Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2020-12       Impact factor: 5.695

2.  PET Imaging of Acidic Tumor Environment With 89Zr-labeled pHLIP Probes.

Authors:  David Bauer; Hannah Visca; Anuradha Weerakkody; Lukas M Carter; Zachary Samuels; Spencer Kaminsky; Oleg A Andreev; Yana K Reshetnyak; Jason S Lewis
Journal:  Front Oncol       Date:  2022-05-19       Impact factor: 5.738

Review 3.  Combination Radioimmunotherapy Approaches and Quantification of Immuno-PET.

Authors:  Jin Su Kim
Journal:  Nucl Med Mol Imaging       Date:  2016-01-26

4.  Noise sensitivity of 89Zr-Immuno-PET radiomics based on count-reduced clinical images.

Authors:  Ananthi Somasundaram; David Vállez García; Elisabeth Pfaehler; Yvonne W S Jauw; Josée M Zijlstra; Guus A M S van Dongen; Willemien C Menke-van der Houven van Oordt; Marc C Huisman; Elisabeth G E de Vries; Ronald Boellaard
Journal:  EJNMMI Phys       Date:  2022-03-03

5.  Focal amyloid and asymmetric tau in an imaging-to-autopsy case of clinical primary progressive aphasia with Alzheimer disease neuropathology.

Authors:  Adam Martersteck; Ivan Ayala; Daniel T Ohm; Callen Spencer; Christina Coventry; Sandra Weintraub; Eileen H Bigio; M -Marsel Mesulam; Changiz Geula; Emily Rogalski
Journal:  Acta Neuropathol Commun       Date:  2022-08-09       Impact factor: 7.578

6.  Production and Semi-Automated Processing of 89Zr Using a Commercially Available TRASIS MiniAiO Module.

Authors:  Vijay Gaja; Jacqueline Cawthray; Clarence R Geyer; Humphrey Fonge
Journal:  Molecules       Date:  2020-06-05       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.